Alzheimer’s AI Biotech IGC Pharma, Inc. (NYSE: IGC) Stock in Focus – More Stocks InsideIGC Pharma, Inc. (
NYSE: IGC) a clinical-stage biotechnology company developing AI-powered Alzheimer’s disease therapies, is gaining investor attention after reporting Q1 2026 financial results and continued progress in its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer’s dementia.
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medicus PharmaThe show broadcasts as sponsored programming featuring TV commercials from IGC Pharma, Inc. (NYSE American:IGC), NRx Pharmaceuticals, Inc. (
NASDAQ:NRXP), Medicus Pharma Ltd. (
NASDAQ:MDCX), and DataVault AI Inc. (
NASDAQ:DVLT).
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau ConferenceResearch highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development.
GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households WorldwideNEW YORK, NY / ACCESS Newswire / May 1, 2026 / New to The Street, one of the longest-running business television brands, today announced the nationwide broadcast of Show #748 airing Saturday, May 2 at 6:30 PM EST on Bloomberg Television as sponsored programming, with simultaneous distribution across the United States, MENA, and Latin America.
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment PhaseOutreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion
New to The Street to Air Show #747 Tonight on Fox Business Network Featuring Performance Golf, CitroTech, Lee Gause, CISO Global, and Lost Soldier Oil and GasThe show broadcasts as sponsored programming and features integrated TV commercial sponsorships from Synergy CHC Corp. (
NASDAQ:SNYR), CISO Global Inc. (
NASDAQ:CISO), Virtuix Holdings Inc. (
NASDAQ:VTIX), IGC Pharma Inc. (NYSE American:IGC), and DataVault AI Inc. (
NASDAQ:DVLT), creating a multi-channel synergy between long-form interviews and national commercial exposure.
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward CompletionBehavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in DementiaAuthorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data ReadoutPOTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's DiseasePOTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's disease, today announced the activation of a new clinical trial site at Tandem Clinical Research A Prolerity Network Site in Metairie, Louisiana, for the Company's ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer's dementia.
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor AwarenessPOTOMAC, MD / ACCESS Newswire / March 30, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced a strategic 12-part national media partnership with New to The Street, a leading financial media platform known for its integrated investor engagement and national television distribution.
New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market PositioningNEW YORK, NY / ACCESS Newswire / March 25, 2026 / New to The Street, a premier financial media platform known for its national television distribution and integrated investor engagement strategy, today announced a strategic 12-part media partnership with IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company leveraging artificial intelligence to develop treatments for Alzheimer's disease and metabolic disorders.
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will demonstrate its Agentic Harmonization Assistant ("AHA"), an artificial intelligence platform designed to automate the integration and analysis of complex biomedical datasets, at the Alzheimer's & Parkinson's Diseases Conference (ADPD) 2026.
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's ResearchPOTOMAC, MD / ACCESS Newswire / February 26, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the filing of utility patent applications covering the architectural framework of its Agentic Harmonization Assistant ("AHA"), an internally developed AI-based data harmonization system.
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital MarketsPOTOMAC, MARYLAND / ACCESS Newswire / February 24, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Ascendiant Capital Markets has issued an updated equity research report covering the Company. According to the Ascendiant Capital Markets, the report raises its price target to $5.00 per share.
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment AdvancesPOTOMAC, MD / ACCESS Newswire / February 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that the Canadian Intellectual Property Office ("CIPO") has issued a Notice of Allowance covering the proprietary composition underlying IGC-AD1, the Company's Phase 2 clinical stage program for agitation associated with Alzheimer's disease.
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital MarketsPOTOMAC, MD / ACCESS Newswire / February 12, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Wednesday, February 18, 2026, at 1:00 p.m. ET.
